Grindeks
| File:Grindeks.gif | |
| Company type | Joint stock company |
|---|---|
| Nasdaq Baltic: GRD1R | |
| Industry | Pharmaceuticals |
| Founded | 11 October 1991[1] |
| Headquarters | , |
Area served | Worldwide |
Key people | Kirovs Lipmans (Chairman)[2] Janis Romanovskis (CEO)[2] |
| Revenue | € 76,2 million (2009)[3] |
 € 5,078 million (2009)[3] | |
| Total assets | 198,324,446 Euro (2022)  |
| Owner | Kirovs Lipmans (33.29%)[2] Anne Lipmane (16.69%)[2] |
Number of employees | 836 (2009)[4] |
| Website | grindeks.lv |
AS Grindeks (branded as Grindex), is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.[1]
One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate.[5][6][7] Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.[8][9][10][11][12]
In 2009, Grindeks had a turnover revenue of €76.2 million with a profit of €5.078 million.[3] Grindeks had 836 employees[4] and the main shareholders were Kirovs Lipmans (33.29%) and Anne Lipmane (16.69%)[2]
References
- ^ a b "Joint Stock Company "Grindeks" Annual Report 2009" (PDF). nasdacomxbaltic.com. 27 April 2010. p. 3. Retrieved 1 November 2010.
- ^ a b c d e "Joint Stock Company "Grindeks" Annual Report 2009" (PDF). nasdacomxbaltic.com. 27 April 2010. p. 4. Retrieved 1 November 2010.
- ^ a b c "Joint Stock Company "Grindeks" Annual Report 2009" (PDF). nasdacomxbaltic.com. 27 April 2010. p. 11. Retrieved 1 November 2010.
- ^ a b "Joint Stock Company "Grindeks" Annual Report 2009" (PDF). nasdacomxbaltic.com. 27 April 2010. p. 32. Retrieved 1 November 2010.
- ^ Biotech Intelligence. http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html (accessed 17 May 2012).
- ^ PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data. http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml (accessed 17 May 2012).
- ^ Evaluate Pharma. https://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=137196 (accessed 17 May 2012).
- ^ Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA (March 2006). "Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics". J. Cardiovasc. Pharmacol. 47 (3): 493–9. doi:10.1097/01.fjc.0000211732.76668.d2. PMID 16633095.
- ^ Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (December 2006). "Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction". J. Cardiovasc. Pharmacol. 48 (6): 314–9. doi:10.1097/01.fjc.0000250077.07702.23. PMID 17204911.
- ^ Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N (May 2000). "Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction". Eur. J. Pharmacol. 395 (3): 217–24. doi:10.1016/S0014-2999(00)00098-4. PMID 10812052.
- ^ Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, Oppermann U, McDonough MA, Schofield CJ (December 2010). "Structural and mechanistic studies on γ-butyrobetaine hydroxylase". Chem. Biol. 17 (12): 1316–24. doi:10.1016/j.chembiol.2010.09.016. PMID 21168767.
- ^ Tars K, Rumnieks J, Zeltins A, Kazaks A, Kotelovica S, Leonciks A, Sharipo J, Viksna A, Kuka J, Liepinsh E, Dambrova M (August 2010). "Crystal structure of human gamma-butyrobetaine hydroxylase". Biochem. Biophys. Res. Commun. 398 (4): 634–9. doi:10.1016/j.bbrc.2010.06.121. PMID 20599753.
 | This Latvian corporation or company article is a stub. You can help Wikipedia by expanding it. |